What do you think the entire medical, pharmaceutical, bioinformatic, etc. industries have been doing for decades? Are you really so arrogant to think that other people are too lazy and stupid to think of your brilliant idea and that you are simply more intelligent than everybody else? Do you really think people haven't been trying?
Or, if they are doing this from quality samples of the population, then we have data to show that, for example, "Yes, Mr. Function Seven, your scan shows elevated levels of Widget-5a enzymes. This is often a precursor to Gadget Cancer, but 30% of the population shows this elevation, while only 1% develop the cancer. It's best to do nothing at this time unless we see further elevation. Have a good day, see you next year"
So either we have this data and we can give accurate advice, or we don't have this data because we're afraid of over-diagnosing non-problems.
I understand the fear, but it's still burying one's head in the sand to not even look.
They are getting quality samples from the population. But it's not a simple as "high enzyme = maybe good chance of cancer". How are you going to get those enzymes from their blood in a way that can be applied to the general population? Before that, how do you know there's not confounding factors (of which they are a LOT)?
> So either we have this data and we can give accurate advice, or we don't have this data because we're afraid of over-diagnosing non-problems.
It's not that easy.
Look at this pathway: https://www.pathwaycommons.org/guide/workflows/rna_seq_to_en...
From here: https://www.pathwaycommons.org/guide/workflows/rna_seq_to_en...
This is what people think the activation of genes is. What they THINK the activation of genes is.
Note the following:
- They don't know all the genes. They are constantly identifying new ones. The number of gene pathways people are pretty sure are complete is small. I don't know if this one is one of the "pretty sure" ones.
- Gene pathways are not just complex in terms of size, they are also non-linear. This is not a computer program, this is a horrible biological mess where biological components constantly and probabilistically emit chemicals.
I don't even think that the pathway I gave you is super representative - it doesn't feature the ridiculous non-linearity and uncertainty that many pathways at the bleeding edge have. They can get much worse.
People are not burying their heads in the sand. They are trying their almighty to dig up from bedrock and reach the sky.
To give people a sense of this, it is not unheard of for large scale bioinformatics platforms to set off alarms and/or zone-level capacity issues with the large cloud providers.
I find it hard to believe I'm reading this sentiment on HN. Do you realize nearly any disruptive idea has do the "arrogant" thing you are speaking off.
Big companies go out of business all the time, industry disappear or wane all the time, big companies/industries with lots of smart people do stupid stuff on the regular. Characterizing the desire to do something other than status quo as "arrogance" is just the bottom of the barrel. I'm glad Semmelweis didn't think the way you do.
Arrogance definitely can play a big role in success of many startup entrepreneurs. Because they think the answer is simple and their arrogance shields them from not trying. So they go down the road and find out the solution is actually quite complicated, but a small percentage succeed in accomplishing the goal.
But it's still arrogance, nonetheless.
Not OP, but yes, I do.
I've had some runins with the health system. At least the parts that I've seen are worse than the dark ages. Especially endocrinologists have absolutely no clue what they are doing. The ones I met don't even have superficial knowledge about their full-time job which they've performed for ~20 years.
And yes, this sounds arrogant. I've tripple checked whether I'm just tripping. Their knowledge is not simply outdated, but never correct to begin with.
I think it's a cultural problem which shows in a lot of areas. Medicine doesn't value human life as much as f.e. air transport
Nothing could be further from the truth. People coming in to "disrupt" only add noise. Eventually those people either understand this and put the effort in to understand the domain or they wander off.
I am skeptical of the “more data is bad” meme of screening hesitancy. It cannot be scientifically true in the strictest sense, and to the degree it’s an accurate assertion, it really seems to reveal an unscientificness to how screening data is used today in practice rather than that in principle more data is bad.
The issue in this subthread was the notion that the only thing between the current state of affairs and high quality screening is a bit of disruption. The problem is hard, smart people are working on it, more smart people are always welcome, it'll still take a while.
It's that 1) sometimes collecting the data itself is harmful at scale. E.g. mammography can cause breast cancer, or cause it to spread. 2) the patients actions as a result of the data can, and does at sufficient scale, cause further harm.
Well, let's remember that the AlphaFold team at Google solved the protein folding problem with a relatively small team in a relatively small number of years after extremely large, well funded companies whose primary business was drug development failed to do so for decades.
So yeah, it's been demonstrated to be possible that the current leaders in a field might be significantly less capable than a different team.
Google's research arm has made leaps and bounds in a particular field (deep learning) and then managed to apply it successfully to a very, very hard problem (protein folding). That other companies failed to adapt Google's successes in deep learning faster than Google is not surprising at all to me.
One might argue that the impact of academic-big pharma collaboration (in the form of funding for research projects related to CASP) is what enabled a company like Google, with no independent desire to collect the massive amounts of wetlab data required to evaluate or develop a tool like AlphaFold, to even participate.
More importantly, AlphaFold hasn't really solved the protein folding problem well enough for drug development. So, the entire debate might be moot.
Did they though? They did extremely well at CASP14, and much better than competing groups. But does this solve protein folding? Deepmind's marketing department would have you think so, but for those of us that work in the field we know that this is not the case.
Furthermore, does protein folding solve the relevant problems of drug design? It solve the forward problem, given an amino acid sequence predict its 3d structure. But for drug design we need the inverse problem, given a specified structure predict an amino acid sequence that produces that structure.
Note that DeepMind drafted off the work of a protein folding guy from academia who had been doing this for decades.
Here's a report of a person whose wife had seasonal affective disorder. He
- deduced that a powerful enough lightbox should be able to cure SAD - didn't find any examples of such treatments in literature - spent $600 to build "LUMINATOR" - "And as of early 2017, with two winters come and gone, Brienne seems to no longer have crippling SAD—though it took a lot of light bulbs, including light bulbs in her bedroom that had to be timed to go on at 7:30am before she woke up, to sustain the apparent cure."
https://www.lesswrong.com/posts/zsG9yKcriht2doRhM/inadequacy...
So mass screen healthy people, collect the data, run models, and get better at it. People like you would rather not try, and this is the same reaction I get from doctors. Applying the same tech that we use to improve ad targeting to disease prediction is a no brainer to anyone whose cushy job doesn't depend on the current medieval state of medical technology.